Atropine: Clinical Trials

29 trials of Atropine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 4 active not recruiting, 3 not yet recruiting, 2 recruiting. 29 Phase 2, 5 Phase 1, 5 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 229Completed 17, Active not recruiting 4, Not yet recruiting 3, Recruiting 2, Unknown 2, Withdrawn 1
Phase 15Completed 3, Not yet recruiting 1, Recruiting 1
Phase 35Completed 3, Not yet recruiting 1, Withdrawn 1

Follow Atropine: new trials by email Literature Review of Atropine trials Research Report on Atropine

Trials (filtered) newest first · largest first

All 29 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer
Sacituzumab Govitecan (SG), Atropine, G-CSF (Granulocyte colony-stimulating factor) - Breast Cancer, Advanced HR+/HER2- Breast Cancer
Phase 2Not yet recruitingMedSIR302026-07-012026-01-28
PROTECT-Study: Prospective Research on Optimizing Atropine Concentration Escalation for Children's Myopia Prevention
0.01% Atropine - Pre-myopia
Phase 1 / Phase 2Not yet recruitingTianjin Medical University Eye Hospital2332026-03-302026-03-04
Efficacy of Topical Atropine Eye Drops for Control of Myopia Progression Among Children Attending Mansoura University Ophthalmic Center
Atropine 0.05% Eye drops, Placebo ophthalmic solution - Myopia
Phase 2 / Phase 3Not yet recruitingMansoura University452025-09-012025-09-09
The Effect of 0.01% Atropine Eye Drops on Axial Length and Refraction in Myopic Children Compared to a Control Group
Atropine 0.01% eye drops - Focus on Axial Length
Phase 2RecruitingLiaquat National Hospital & Medical College602025-07-132026-03-06
A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control
SHJ002, Atropine - Myopia, Progressive
Phase 2Active not recruitingSunhawk Vision Biotech, Inc.1402025-01-222026-01-23
Recovery Times of Half Dose Sugammadex and Neostigmine for Rocuronium-induced Neuromuscular Blockade
Sugammadex 1 mg/kg, Neostigmine + Atropine - Neuromuscular Blocking Agents, Reversal of Neuromuscular Blockade
Phase 1 / Phase 2RecruitingUniversitas Padjadjaran602024-11-052025-01-28
Early Intervention for Premyopic Children
MiyoSmart Spectacles, 0.01% atropine - Myopia, Preschool
Phase 2Active not recruitingNational Yang Ming Chiao Tung University Hospital2402024-10-062025-06-12
Role of Intralipid in Management of Organophosphorus Poisoning
Intralipid, 20% Intravenous Emulsion, Intravenous Atropine Sulfate - Organophosphorus Poisoning
Phase 2 / Phase 3WithdrawnAmani Hassan Abdel-Wahab2024-04-012025-10-03
Dexmedetomidine Infusion Dose Versus Rapid Bolus Dose Before Tracheal Intubation.
Dexmedetomidine infusion, Dexmedetomidine bolus, Atropine Sulfate - Dexmedetomidine, Intubation Complication
Phase 2CompletedKasr El Aini Hospital702024-04-012026-07-09
Myopia Control: a Comparison Study Between Atropine and MiSight
Atropine, MiSight contact lenses - Myopia
Phase 2Active not recruitingAnn & Robert H Lurie Children's Hospital of Chicago3482023-05-022026-07-22
Safety, Tolerability and Pharmacodynamics Evaluation of CBT-009 Eye Drop
CBT-009, Vehicle, Atropine Sulfate - Myopia, Progressive
Phase 1 / Phase 2CompletedCloudbreak Therapeutics, LLC842022-07-202023-01-27
Outcome of Moderate Severity in OPC Poisoning Patients When Treated With Pralidoxime
Pralidoxime, Atropine - Organophosphorus Poisoning
Phase 2CompletedSir Salimullah Medical College Mitford Hospital962022-06-012024-10-09
The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS
Scopolamine, atropine, edaravone and dexmedetomidine, Edaravone - Amyotrophic Lateral Sclerosis, Respiratory Function
Phase 2UnknownRuijin Hospital302020-11-012020-10-14
Pharmacokinetic-pharmacodynamic Analysis of Sugammadex for Conventional Reversal in Children
Sugammadex Injection 2mg/kg, Sugammadex Injection 4mg/kg, Sugammadex Injection 8mg/kg - Anesthesia, General, Neuromuscular Blockade
Phase 2CompletedSeoul National University Hospital322020-04-292022-02-10
Pharmacokinetic-pharmacodynamic Analysis of Sugammadex in Children
Sugammadex Injection 2mg/kg, Sugammadex Injection 4mg/kg, Sugammadex Injection 8mg/kg - Anesthesia, General, Neuromuscular Blockade
Phase 2CompletedSeoul National University Hospital402019-08-122022-11-14
Low-dose Atropine for the Prevention of Myopia Progression in Danish Children
0.1% atropine and 0.01% atropine, 0.01% atropine, 0.9% Sodium-chloride - Myopia
Phase 2CompletedLine Kessel972019-05-302025-06-29
Low-dose Atropine Eye Drops to Reduce Progression of Myopia in Children in the United Kingdom
Atropine Sulfate, Placebo - Myopia
Phase 2Active not recruitingBelfast Health and Social Care Trust2892019-04-032023-09-07
Side Effects of Atropine (SEA) Study
0.01% concentration atropine drops - Myopia
Phase 1 / Phase 2CompletedJeffrey J. Walline, OD PhD312018-07-232022-12-02
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
E7 TCR cells, Aldesleukin, Fludarabine - Papillomavirus Infections, Cervical Intraepithelial Neoplasia
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)2242017-01-272026-03-09
The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer (TIVA/TCI-BC)
Lidocaine, Sevoflurane, TIVA-TCI - Breast Cancer
Phase 2CompletedIuliu Hatieganu University of Medicine and Pharmacy1202016-08-012019-10-29

Showing 20 of 29. Sign in to see all of them.

Conditions studied

Myopia (7)  ·  Breast Neoplasms (2)  ·  Myopia, Degenerative (2)  ·  Organophosphate Poisoning (2)  ·  Amyotrophic Lateral Sclerosis (1)  ·  Bradycardia (1)  ·  Carcinoma in Situ (1)  ·  Heart Arrest (1)  ·  Hemorrhage (1)  ·  Hemostatic Disorders (1)  ·  Hypospadias (1)  ·  Hypotension (1)  ·  Pain (1)  ·  Papillomavirus Infections (1)  ·  Photophobia (1)

Sponsors

Assiut University (2)  ·  Centre Hospitalier Intercommunal Creteil (2)  ·  Seoul National University Hospital (2)  ·  Amani Hassan Abdel-Wahab (1)  ·  Ann & Robert H Lurie Children's Hospital of Chicago (1)  ·  Belfast Health and Social Care Trust (1)  ·  Cloudbreak Therapeutics, LLC (1)  ·  Isfahan University of Medical Sciences (1)  ·  Iuliu Hatieganu University of Medicine and Pharmacy (1)  ·  Jeffrey J. Walline, OD PhD (1)  ·  Kasr El Aini Hospital (1)  ·  Liaquat National Hospital & Medical College (1)  ·  Line Kessel (1)  ·  Magna Pharmaceuticals, Inc. (1)  ·  Mansoura University (1)

Countries

United States (5)  ·  Egypt (3)  ·  France (2)  ·  South Korea (2)  ·  Taiwan (2)  ·  Australia (1)  ·  Austria (1)  ·  Bangladesh (1)  ·  China (1)  ·  Denmark (1)  ·  Indonesia (1)  ·  Norway (1)  ·  Pakistan (1)  ·  Romania (1)  ·  United Kingdom (1)

Top investigators

Augusto Azuara-Blanco, PhD FRCOphth (1)  ·  Der-Chong Tsai, MD, PhD (1)  ·  Hamdy A. Youssef, Professor (1)  ·  Hee-Soo Kim, M.D, Ph.D. (1)  ·  Hee-Soo Kim, M.D., Ph.D. (1)  ·  Hina Nadeem, MBBS (1)  ·  Jeffrey Walline (1)  ·  Jun Liu, Professor (1)  ·  Lars Wik, MD, PhD (1)  ·  Magdalena Stec, OD (1)  ·  Meryl Vedrenne-Cloquet, MD (1)  ·  Michael Wolzt, MD (1)  ·  Scott M Norberg, D.O. (1)  ·  Stephen J Pollard, MD (1)  ·  Tanya Revell, MD (1)

Results publications

PMID 19934423, PMID 24247230, PMID 25794212, PMID 29715354, PMID 30881948, PMID 31653669, PMID 32616309, PMID 33301785, PMID 33558725, PMID 37124204, PMID 37904082, PMID 39422837, PMID 39522589, PMID 39739826, PMID 42276557

NIH funding

2017 (1), 2025 (1)